S1 Episode 1: Risk Stratification in Myelofibrosis: Which Model Should You Use?

Join Drs Tania Jain and Pankit Vachhani as they discuss the nuance involved in the risk stratification of myelofibrosis and the latest research in prefibrotic myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999593. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary Myelofibrosis: Risk Stratification by IPSS Identifies Patients With Poor Clinical Outcome https://pubmed.ncbi.nlm.nih.gov/23644853/

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/

Predicting Survival After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model https://pubmed.ncbi.nlm.nih.gov/32717433/

New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment https://pubmed.ncbi.nlm.nih.gov/18988864/

GIPSS: Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29654267/

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project https://ashpublications.org/blood/article/124/21/405/115226/Mutation-Enhanced-International-Prognostic-Scoring

MIPSS70+ v2.0 Predicts Long-Term Survival in Myelofibrosis After Allogeneic HCT With the Flu/Mel Conditioning Regimen https://pubmed.ncbi.nlm.nih.gov/30622146/

MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/29708808/

U2AF1 Mutation Types in Primary Myelofibrosis: Phenotypic and Prognostic Distinctions https://pubmed.ncbi.nlm.nih.gov/29535431/

A Clinical-Molecular Prognostic Model to Predict Survival in Patients With Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/28561069/

MYSEC Prognostic Model Risk Calculator (MYSEC-PM) http://www.mysec-pm.eu/

A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/

A Simple Prognostic System in Patients With Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation: A CIBMTR/EBMT Analysis https://pubmed.ncbi.nlm.nih.gov/37134306/

SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38341324/

IPSET Thrombosis Risk for ET https://thehematologist.org/ipset-thrombosis/